A patent review of IDO1 inhibitors for cancer

Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities

(2018) Jae Eun Cheong et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitors

(2017) Finith E Jernigan et al.   Future Medicinal Chemistry

Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate

(2017) Stefano Crosignani et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of a Covalent Kinase Inhibitor from a DNA-Encoded Small-Molecule Library × Protein Library Selection

(2017) Alix I. Chan et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Targeting TDO in cancer immunotherapy

(2017) Cheng-Peng Yu et al.   MEDICAL ONCOLOGY

Lessons Learned from Two Decades of Anticancer Drugs

(2017) Zhichao Liu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

(2017) Eddy W. Yue et al.   ACS Medicinal Chemistry Letters

Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1

(2017) Ariel Lewis-Ballester et al.   Nature Communications

Combinatorial approach to cancer immunotherapy: strength in numbers

(2016) Anna E. Vilgelm et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4

(2016) Katharina Ochs et al.   JOURNAL OF NEUROCHEMISTRY

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

Perspectives in Medicinal Chemistry: Metalloprotein Inhibitors: What Have We Made and What is the Next Step?

(2015) Xing-Xing Zhang et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Metalloprotein Inhibitors for the Treatment of Human Diseases

(2015) Yang Yang et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors

(2015) Ute F. Röhrig et al.   JOURNAL OF MEDICINAL CHEMISTRY

Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1

(2015) Yi-Hui Peng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR

(2015) Ulrike M. Litzenburger et al.   Oncotarget

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Crystal Structures and Structure–Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors

(2014) Shingo Tojo et al.   ACS Medicinal Chemistry Letters

Trial watch: IDO inhibitors in cancer therapy

(2014) Erika Vacchelli et al.   OncoImmunology

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 – 2012)

(2013) Eduard Dolušić et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Development of a histone deacetylase 6 inhibitor and its biological effects

(2013) J.-H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

(2012) L. Pilotte et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen

(2011) Jason R. Smith et al.   BIOORGANIC & MEDICINAL CHEMISTRY

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

(2011) Maria T Pallotta et al.   NATURE IMMUNOLOGY

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism

(2010) N. T. Nguyen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling

(2010) Brett C. DiNatale et al.   TOXICOLOGICAL SCIENCES